The glucose-phosphorylating enzyme glucokinase has a crucial role in glucose homeostasis as 'glucose sensor' of the insulin-producing pancreatic β-cells and as a regulatory step in the conversion of glucose to glycogen, as well as in gluconeogenesis in the liver.
Autosomal dominant activating or inactivating mutations of glucokinase in humans and rodents cause hyperinsulinism and diabetes, respectively.
The activating point mutations are clustered at a location in the enzyme structure that is distinct from the substrate binding site, which suggests that glucokinase has an allosteric activator site.
These and other observations highlighted glucokinase as a potential drug target.
Glucokinase activators (GKAs) have been discovered recently that stimulate the enzyme allosterically by lowering its glucose S0.5 (the concentration of glucose that allows half-maximal activity of the enzyme) and Hill coefficient (nH) and increasing its catalytic constant (kcat).
At present, approximately 100 patents on low molecular-weight compounds with GKA characteristics have been disclosed by the pharmaceutical industry.
GKAs lower blood glucose levels in normal laboratory animals and humans by stimulating insulin release and enhancing hepatic glucose uptake.
GKAs lower blood glucose in animal models of type 2 diabetes and in humans with type 2 diabetes.
An assessment of the current status of basic and clinical GKA-related research indicates that this new class of anti-diabetic drugs shows promise for monotherapy or combination drug therapy of type 2 diabetes.
Glucokinase, a unique isoform of the hexokinase enzymes, which are known to phosphorylate D-glucose and other hexoses, was identified during the past three to four decades as a new, promising drug target for type 2 diabetes. Glucokinase serves as a glucose sensor of the insulin-producing pancreatic islet β-cells, controls the conversion of glucose to glycogen in the liver and regulates hepatic glucose production. Guided by this fundamental knowledge, several glucokinase activators are now being developed, and have so far been shown to lower blood glucose in several animal models of type 2 diabetes and in initial trials in humans with the disease. Here, the scientific basis and current status of this new approach to diabetes therapy are discussed.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Nature Medicine Open Access 12 May 2022
Nature Communications Open Access 06 April 2022
Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma
Scientific Reports Open Access 12 March 2021
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Matschinsky, F. M. et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55, 1–12 (2006).
Grimsby, J. et al. Allosteric activation of islet and hepatic glucokinase: a potential new approach to diabetes therapy. Diabetes Abstr. 50 (Suppl. 2), A115 (2001).
Doliba, N. et al. Novel pharmacological glucokinase activators enhance glucose metabolism, respiration and insulin release in isolated pancreatic islets demonstrating a unique therapeutic potential (Abstr. 1495-P; 61st ADA Meeting, Philadelphia). Diabetes 50 (Suppl. 2), A359 (2001).
Cuesta-Munoz, A. L. et al. Novel pharmacological glucokinase activators partly or fully reverse the catalytic defects of inactivating glucokinase missense mutants that cause MODY-2. Diabetes Abstr. 50 (Suppl. 2), A109 (2001).
Grimsby, J. et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301, 370–373 (2003). First peer-reviewed report on the discovery and potential of GKAs.
Grimsby, J., Matschinsky, F. M. & Grippo J. F . in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes. Vol. 16. (eds Matschinsky, F. M. & Magnuson, M. A.) 360–378 (Karger, Basel, 2004).
Meglasson, M. D. & Matschinsky, F. M. in Diabetes/Metabolism Reviews 3: Regulation of Insulin Secretion (ed. DeFronzo, R. A.) 163–214 (John Wiley & Sons, New York, 1986).
Matschinsky, F. M. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45, 223–241 (1996).
Walker, D. G. & Rao, S. The role of glucokinase in the phosphorylation of glucose by rat liver. Biochem. J. 90, 360–368 (1964). First peer-reviewed report on the presence and significance of hepatic glucokinase.
Sols, A., Salas, M. & Vinuela, E. Induced biosynthesis of liver glucokinase. Adv. Enzyme Regul. 2, 177–188 (1964).
Sharma, C., Manjeshwar, R. & Weinhouse, S. Hormonal and dietary regulation of hepatic glucokinase. Adv. Enzyme Regul. 2, 189–200 (1964).
Matschinsky, F. M. & Ellerman, J. E. Metabolism of glucose in the islets of Langerhans. J. Biol. Chem. 243, 2730–2736 (1968). First report on the presence and significance of glucokinase in mouse pancreatic islets.
Bedoya, F. J., Matschinsky, F. M., Shimizu, T., O'Neil, J. J. & Appel, M. C. Differential regulation of glucokinase activity in pancreatic islets and liver of the rat. J. Biol. Chem. 261, 10760–10764 (1986). First report providing evidence for differential control of glucokinase expression, primarily by glucose in pancreatic islet tissue and by insulin in the liver.
Froguel, P. et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 356, 162–164 (1992).
Hattersley, A. T. et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 339, 1307–1310 (1992).
Edghill, E. L. & Hattersley, A. T. in Pancreatic Beta Cell in Health and Disease (eds Seino, S. & Bell, G. I.) 399–430 (Springer, Tokyo2008). Authoritative review of glucokinase-linked hyperglycaemia syndromes.
Glaser, B. et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N. Engl. J. Med. 338, 226–230 (1998). First report on glucokinase-linked hyperinsulinism syndrome.
Christesen, H. et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 51, 1240–1246 (2002).
Gloyn, A. L. et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52, 2433–2440 (2003).
MCuesta-uñoz, A. L. et al. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 53, 2164–2168 (2004).
Njolstad, P. R. et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N. Engl. J. Med. 344, 1588–1592 (2001).
Njølstad, P. R. et al. Permanent neonatal diabetes mellitus due to glucokinase deficiency — an inborn error of the glucose–insulin signaling pathway. Diabetes 52, 2854–2860 (2003).
Brocklehurst, K. J. et al. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 53, 535–541 (2004).
Kamata, K., Mitsuya, M., Nishimura, T., Eiki, J. & Nagata, Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure (Camb.) 12, 429–438 (2004). Seminal report on the crystal structures of the unliganded 'super-open' form and the glucose- and GKA-containing ternary complex of the 'closed-form' of glucokinase; also provides a plausible model explaining the cooperative kinetics of glucokinase with regard to glucose.
Dunten, P. et al. in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes. vol. 16 (eds Matschinsky, F. M. & Magnuson, M. A.) 145–154 (Karger, Basel, 2004).
Futamura, M. et al. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J. Biol. Chem. 281, 37668–37674 (2006).
Efanov, A. M. et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 146, 3696–3701 (2005).
Fyfe, M. C. T. et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 50, 1277–1287 (2007).
Leighton, B., Atkinson, A., Coope, G. J. & Coghlan, M. P. Improved glycemic control after sub-acute administration of a glucokinase activator to male Zucker (fa/fa) rats. Diabetes Abstr. 56, 0377–OR (2007).
Sorhede Winzell, M. et al. Glucokinase activation reduces glycemia and improves glucose tolerance in mice with high-fat diet-induced insulin resistance. Diabetes Abstr. 56, 1482—P (2007).
Nakamura, A. et al. Impact of small molecule glucokinase activator on glucose metabolism in response to high fat diet in mice with β-cell specific haploinsufficiency of glucokinase gene. Diabetes Abstr. 56, 529–P (2007).
Coghlan, M. & Leighton, B. Glucokinase activators in diabetes management. Expert Opin. Investig. Drugs 17, 145–167 (2008).
Guertin, K. R & Grimsby, J. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr. Med. Chem. 13, 1839–1843 (2006).
Sarabu, R., Berthel, S. J., Kester, R. F. & Tilley, J. W. Glucokinase activators as new type 2 diabetes therapeutic agents. Expert Opin. Ther. Patents 18, 759–768 (2008).
Sarabu, R. & Grimsby, J. Targeting glucokinase activation for the treatment of type 2 diabetes — a status review. Curr. Opin. Drug Discov. Devel. 8, 631–637 (2005).
Cárdenas, M. L., Cornish-Bowden, A. & Ureta, T. Evolution and regulatory role of the hexokinases. Biochim. Biophys. Acta 1401, 242–264 (1998).
Wilson, J. E. in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes. vol. 16 (eds Matschinsky, F. M. & Magnuson, M. A.) 18–30 (Karger, Basel, 2004).
Iynedjian, P. B. Mammalian glucokinase and its gene. Biochem. J. 293, 1–13 (1993).
Iynedjian, P. B. in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes. vol. 16 (eds Matschinsky, F. M. & Magnuson, M. A.) 155–168 (Karger, Basel, 2004).
Postic, C., Shiota, M. & Magnuson, M. A. Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog. Horm. Res. 56, 195–218 (2001).
Iynedjian, P. B. Molecular physiology of mammalian glucokinase. Cell. Mol. Life Sci. 66, 27–42 (2008).
Vandercammen, A. & Van Schaftingen, E. The mechanism by which rat liver glucokinase is inhibited by the regulatory protein. Eur. J. Biochem. 191, 483–489 (1990). Original report describing the discovery of the glucokinase regulatory protein in liver tissue.
Vandercammen, A. & Van Schaftingen, E. Competitive inhibition of liver glucokinase by its regulatory protein. Eur. J. Biochem. 200, 545–551 (1991).
Detheux, M., Vandercammen, A. & Van Schaftingen, E. Effectors of the regulatory protein acting on liver glucokinase: a kinetic investigation. Eur. J. Biochem. 200, 553–561 (1991).
Veiga-da-Cunha, M. & Van Schaftingen, E. Identification of fructose 6-phosphate- and fructose 1-phosphate-binding residues in the regulatory protein of glucokinase. J. Biol. Chem. 277, 8466–8473 (2002).
Agius, L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem. J. 414, 1–18 (2008).
Agius, L. & Peak, M. Intracellular binding of glucokinase in hepatocytes and translocation by glucose, fructose and insulin. Biochem. J. 296, 785–796 (1993).
Agius, L., Peak, M. & Van Schaftingen, E. The regulatory protein of glucokinase binds to the hepatocyte matrix, but, unlike glucokinase, does not translocate during substrate stimulation. Biochem. J. 309, 711–713 (1995).
Agius, L. The physiological role of glucokinase binding and translocation in hepatocytes. Adv. Enzyme Regul. 38, 303–331 (1998).
Payne, V. A., Arden, C., Lange, A. J. & Agius, L. Contributions of glucokinase and phosphofructokinase-2/fructose bisphosphatase-2 to the elevated glycolysis in hepatocytes from Zucker fa/fa rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R618–R625 (2007).
Baltrusch, S., Wu, C., Okar, D. A., Tiedge, M. & Lange, A. J. in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes. vol. 16 (eds Matschinsky, F. M. & Magnuson, M. A.) 262–274 (Karger, Basel, 2004).
Danial, N. N. et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424, 952–956 (2003).
Danial, N. N. et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nature Med. 14, 144–153 (2008). Report on the presence and dual role of the pro-apoptotic protein BAD in pancreatic islet tissue — that is, as regulator of β-cell replication and as a protein-binding partner of mitochondrial glucokinase, controlling glucose-stimulated insulin release.
Heredia, V. V., Thomson, J., Nettleton, D. & Sun, S. Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis. Biochemistry 45, 7553–7562 (2006).
Kim, Y. B., Kalinowski, S. S. & Marcinkeviciene, J. A pre-steady state analysis of ligand binding to human glucokinase: evidence for a preexisting equilibrium. Biochemistry 46, 1423–1431 (2007).
Zhang, J. et al. Conformational transition pathway in the allosteric process of human glucokinase. Proc. Natl Acad. Sci. USA 103, 13368–13373 (2006).
Zelent, B. et al. Sugar binding to recombinant wild-type and mutant glucokinase monitored by kinetic measurement and tryptophan fluorescence. Biochem J. 413, 269–280 (2008).
Lin, S. X. & Neet, K. E. Demonstration of a slow conformational change in liver glucokinase by fluorescence spectroscopy. J. Biol. Chem. 265, 9670–9675 (1990). Authoritative discussion of the 'slow transition model', which explains the sigmoidal glucose dependency of the glucokinase reaction.
Neet, K. E. & Ainslie, G. R. Hysteretic enzymes. Methods Enzymol. 64, 192–226 (1980).
Cornish-Bowden, A. & Cárdenas, M. L. in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes. Vol. 16 (eds Matschinsky, F. M. & Magnuson, M. A.) 125–134 (Karger, Basel, 2004). Brief expert discussion of the 'mnemonic model' explaining the sigmoidal glucose dependency of the glucokinase reaction.
Jetton, T. L. et al. Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. J. Biol. Chem. 269, 3641–3654 (1994).
Zelent, D. et al. A glucose sensor role for glucokinase in anterior pituitary cells. Diabetes 55, 1923–1929 (2006).
Sorenson, R. L., Stout, L. E., Brelje, T. C., Jetton, T. & Matschinsky, F. M. Immunohistochemical evidence for the presence of glucokinase in the gonadotropes and thyrothropes of the anterior pituitary gland of rat and monkey. J. Histochem. Cytochem. 55, 555–566 (2007). First report on the presence and possible role of glucokinase in gonadotropes of the pituitary gland.
Zelent, D. et al. Glucokinase and glucose homeostasis: proven concepts and new ideas. Biochem. Soc. Trans. 33, 306–310 (2005).
Leibiger, B. et al. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic β cells. Mol. Cell 7, 559–570 (2001).
Levin, B. E., Routh, V. H., Kang, L., Sanders, N. M. & Dunn-Meynell, A. A. Neuronal glucosensing: what do we know after 50 years? Diabetes 53, 2521–2528 (2004).
Levin, B. E., Becker, T. C., Eiki, J.-I., Zhang, B. B. & Dunn-Meynell, A. A. Ventromedial hypothalamic glucokinase is an important mediator of the counterregulatory response to insulin-induced hypoglycemia. Diabetes 57, 1371–1379 (2008).
Mountjoy, P. D. & Rutter, G. A. Glucose sensing by hypothalamic neurones and pancreatic islet cells: AMPle evidence for common mechanisms? Exp. Physiol. 92, 311–319 (2007).
Thorens, B. The Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes. Vol. 16 (eds Matschinsky, F. M. & Magnuson, M. A.) 327–338 (Karger, Basel, 2004).
Donovan, C. M., Hamilton-Wessler, M., Halter, J. B. & Bergman, R. N. Primacy of liver glucosensors in the sympathetic response to progressive hypoglycemia. Proc. Natl Acad. Sci. USA 91, 2863–2867 (1994).
Cherrington, A. D. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48, 1198–1214 (1999). Authoritative discussion of the regulation of hepatic glucose metabolism, including evaluation of mechanisms underlying the 'portal signal'.
Trus, M. D. et al. Regulation of glucose metabolism in pancreatic islets. Diabetes 30, 911–922 (1981).
Bedoya, F. D., Wilson, J. M., Ghosh, A. K., Finegold, D. & Matschinsky, F. M. The glucokinase glucose sensor in human pancreatic islet tissue. Diabetes 35, 61–67 (1986). First report on quantitative measurements and significance of glucokinase in normal human pancreatic islet tissue.
Liang, Y., Najafi, H. & Matschinsky, F. M. Glucose regulates glucokinase activity in cultured islets from rat pancreas. J. Biol. Chem. 265, 16863–16866 (1990).
Liang, Y. Concordant glucose induction of glucokinase, glucose usage and glucose stimulated insulin release in pancreatic islets maintained in organ culture. Diabetes 41, 792–806 (1992).
Tal, M., Liang, Y., Najafi, H., Lodish, H. F. & Matschinsky, F. M. Expression and function of GLUT-1 and GLUT-2 glucose transporter isoforms in cells of cultured rat pancreatic islets. J. Biol. Chem. 267, 17241–17247 (1992).
Newgard, C. B. & Matschinsky, F. M. in The Endocrine System Vol. II: The Endocrine Pancreas and Regulation of Metabolism. Handbook of Physiology. 125–151 (Oxford Univ. Press, Oxford 2001).
MacDonald, M. J. Feasibility of a mitochondrial pyruvate malate shuttle in pancreatic islets. J. Biol. Chem. 270, 20051–20058 (1995).
Li, C. et al. Elimination of KATP channels in mouse islets results in elevated [U-13C]glucose metabolism, glutaminolysis, and pyruvate cycling but a decreased γ-aminobutyric acid shunt. J. Biol. Chem. 283, 17238–17249 (2008).
Henquin, J. C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49, 1751–1760 (2000).
Prentki, M. & Matschinsky, F. M. Ca2+, cAMP and phosphoinositide derived messengers in the coupling mechanisms of insulin secretion. Physiol. Rev. 67, 1185–1248 (1987).
Hardie, D. G. & Carling, D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur. J. Biochem. 246, 259–273 (1997).
Trus, M. D et al. A comparison of the effects of glucose and acetylcholine on insulin release and intermediary metabolism in rat pancreatic islets. J. Biol. Chem. 254, 3921–3929 (1979).
Trus, M., Warner, H. & Matschinsky, F. M. Effects of glucose on insulin release and on intermediary metabolism of isolated perifused pancreatic islets from fed and fasted rats. Diabetes 29, 1–14 (1980).
Gromada, J., Franklin, I. & Wollheim, C. B. α-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 28, 84–116 (2007).
Liu, Y.-J., Vieira, E. & Gylfe, E. A store-operated mechanism determines the activity of the electrically excitable glucagon-secreting α-cell. Cell Calcium 35, 357–365 (2004).
Vieira, E., Salehi, A. & Gylfe, E. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia, 50, 370–379 (2007).
Pagliara, A. S., Stillings, S. N., Hover, B., Martin, D. M. & Matschinsky, F. M. Glucose modulation of amino acid-induced glucagon and insulin release in the isolated perfused rat pancreas. J. Clin. Invest. 54, 819–832 (1974).
Pagliara, A. S., Stillings, S. N., Haymond, M. W., Hover, B. A. & Matschinsky, F. M. Insulin and glucose as modulators of the amino acid-induced glucagon release in the isolated pancreas of alloxan and streptozotocin diabetic rats. J. Clin. Invest. 55, 244–255 (1975).
Matschinsky, F. M., Pagliara, A. S., Stillings, S. N. & Hover, B. A. Glucose and ATP levels in pancreatic islet tissue of normal and diabetic rats. J. Clin. Invest. 58, 1193–1200 (1976).
Matschinsky, F. M. et al. Hormone secretion and glucose metabolism in islets of Langerhans of the isolated perfused pancreas from normal and streptozotocin diabetic rats. J. Biol. Chem. 251, 6053–6061 (1976).
Pagliara, A. S., Stillings, S. N., Zawalich, W. S., Williams, A. D. & Matchinsky, F. M. Glucose and 3-O-methylglucose protection against alloxan poisoning of pancreatic alpha and beta cells. Diabetes 26, 973–979 (1977).
Matschinsky, F. M., Rujanavech, C., Pagliara, A. & Norfleet, W. T. Adaptations of alpha2- and beta-cells of rat and mouse pancreatic islets to starvation, to refeeding after starvation, and to obesity. J. Clin. Invest. 65, 207–218 (1980).
Reimann, F., Ward, P. S. & Gribble, F. M. Signalling mechanisms underlying the release of glucagon-like peptide-1. Diabetes 55 (Suppl. 2), S78–S85 (2006).
Reimann, F., Williams, L., da Silva Xavier, G., Rutter, G. A. & Gribble, F. M. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 47, 1592–1601 (2004).
Reimann, F. et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 8, 532–539 (2008).
Murphy, R. et al. Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor. Diabetologia 52, 154–159 (2008).
Matschinsky, F. M. in Pancreatic Beta Cell in Health and Disease (eds Seino, S. & Bell, G. I.) 451–463 (Springer, Tokyo, 2008).
Hille, B., Tse, A. Tse, F. W. & Bosma, M. M. Signaling mechanisms during the response of pituitary gonadotropes to GnRH. Recent Prog. Horm. Res. 50, 75–95 (1995).
Torres, T. P. et al. Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in Zucker diabetic fatty rats. Diabetes 24 Oct 2008 (doi:10.2337/db08-1119)
Nelson, D. L. & Cox, M. M. (eds) Lehninger Principles of Biochemistry 569–613 (W. H. Freeman, New York, 2008).
Nelson, D. L. & Cox, M. M. (eds) Lehninger Principles of Biochemistry 901–944 (W. H. Freeman, New York, 2008).
Magnuson, M. A. & Kim, K.-A. Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes Vol. 16 (eds Matschinsky, F. M. & Magnuson, M. A.) 289–300 (Karger, Basel, 2004).
Gloyn, A. L. et al. in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes Vol. 16 (eds Matschinsky, F. M. & Magnuson, M. A.) 92–109 (Karger, Basel, 2004).
Pino, M. F. Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations. J. Biol. Chem. 282, 13906–13916 (2007).
LeRoith, D., Taylor, S. I., & Olefsky, J. M. (eds) Diabetes Mellitus: A Fundamental and Clinical Text. 3rd edn (Lippincott Williams & Wilkins, Philadelphia, 2004).
McCarthy, M. I. & Froguel, P. Genetic approaches to the molecular understanding of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 283, E217–E225 (2002).
Chen, W. M. et al. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J. Clin. Invest. 118, 2620–2628 (2008).
Wilms, B., Ben-Ami, P. & Söling, H. D. Hepatic enzyme activities of glycolysis and gluconeogenesis in diabetes of man and laboratory animals. Horm. Metab. Res. 2, 135–141 (1970).
Caro, J. F. et al. Liver glucokinase: decreased activity in patients with type II diabetes. Horm. Metab. Res. 27, 19–22 (1995).
Liang, Y. et al. In situ glucose uptake and glucokinase activity of pancreatic islets in diabetic and obese rodents. J. Clin. Invest. 93, 2473–2481 (1994).
Bedoya, F. J., Oberholtzer, J. C. & Matschinsky, F. M. Glucokinase in B-cell-depleted islets of Langerhans. J. Histochem. Cytochem. 35, 1089–1093 (1987).
Deng, S. et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53, 624–632 (2004).
Nolte, M. S. & Karam, J. H. in Basic and Clinical Pharmacology 10th edn (ed. Katzung, B. G.) 683–705 (McGraw-Hill, New York, 2007).
Qian-Cutrone, J. et al. Glucolipsin A and B, two new glucokinase activators produced by Streptomyces purpurogeniscleroticus and Nocardia vaccinii. J. Antibiot. (Tokyo) 52, 245–255 (1999).
Gloyn, A. L. et al. Insights into the structure and regulation of glucokinase from a novel mutation (V62M) which causes maturity-onset diabetes of the young. J. Biol. Chem. 280, 14105–14113 (2005).
Sagen, J. V. et al. From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. Diabetes 55, 1713–1722 (2006).
Ralph, E. C., Thomson, J., Almaden, J. & Sun, S. Glucose modulation of glucokinase activation by small molecules. Biochemistry 47, 5028–5036 (2008).
Johnson, D. et al. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes 56, 1694–1702 (2007).
Zhi, J. et al. A novel glucokinase activator RO4389620 improved fasting and postprandial plasma glucose in type 2 diabetic patients. Diabetologia 51 (Suppl. 1), 23 Abstr. 42 (2008).
Bonadonna, R. C. et al. Glucokinase activator RO4389620 improves beta cell function and plasma glucose indexes in patients with type 2 diabetes. Diabetologia 51 (Suppl. 1), 371 Abstr. 927 (2008). Abstract describing improvement of β-cell function by GKAs in patients with T2DM.
Zhai, S. et al. Phase I assessment of a novel glucose activator RO4389620 in healthy male volunteers. Diabetologia 51 (Suppl. 1) 372 Abstr. 928 (2008).
Coope, G. J. et al. Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats. Brit. J. Pharmacol. 149, 328–335 (2006).
Vaxillaire, M. et al. for the DESIR Study Group. The common P446L polymorphism in GCAR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 57, 2253–2257 (2008).
Orho-Melander, M. et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57, 3112–3121 (2008).
Sparsø, T. et al. Impact of polymorphisms in WFS1 on prediabetic phenotypes in a population-based sample of middle-aged people with normal and abnormal glucose regulation. Diabetologia 51, 70–75 (2008).
Terauchi, Y. et al. Glucokinase and IRS-2 are required for compensatory β cell hyperplasia in response to high-fat diet-induced insulin resistance. J. Clin. Invest. 117, 246–257 (2007). Report of studies that strongly suggest that glucokinase and insulin-receptor substrate-2 are required for compensatory β-cell hyperplasia in diet-induced obesity and diabetes.
Takamoto, I. et al. Crucial role of insulin receptor substrate-2 in compensatory β-cell hyperplasia in response to high fat diet-induced insulin resistance. Diabetes Obes. Metab. 10 (Suppl. 4), 147–156 (2008).
Tourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M. & Portha, B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50, 1562–1570 (2001).
Panten, U., Schwanstecher, M. & Schwanstecher, C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp. Clin. Endocrinol. Diabetes 104, 1–9 (1996).
Hirasawa, A., Hara, T., Katsuma, S., Adachi, T. & Tsujimoto, G. Free fatty acid receptors and drug discovery. Biol. Pharm. Bull. 31, 1847–1851 (2008).
Arden,C., Baltrusch, S. & Agius, L. Glucokinase regulatory protein is associated with mitochondria in hepatocytes. FEBS Lett. 580, 2065–2070 (2006).
Miwa, I., Toyoda, Y. & Yoshie, S. in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes. vol. 16 (eds Matschinsky, F. M. & Magnuson, M. A.) 350–359 (Karger, Basel, 2004).
Moore, M. C., Davis, S. N., Mann, S. L. & Cherrington, A. D. Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. Diabetes Care 24, 1882–1887 (2001).
Grimsby, J. et al. Characterization of glucokinase regulatory protein deficient mice. J. Biol. Chem. 275, 7826–7831 (2000).
Munoz-Alonzo, M. J. et al. A novel cytosolic dual specificity phospatase, interacting with glucokinase, increases glucose phosphorylation rate. J. Biol. Chem. 275, 32406–32412 (2000).
Shiraishi, A. et al. A novel glucokinase regulator in pancreatic beta-cells: precursor of propionyl-CoA carboxylase beta-subunit interacts with glucokinase and augments its activity. J. Biol. Chem. 276, 2325–2328 (2001).
Rizzo, M. A. & Piston, D. W. Regulation of beta-cell glucokinase by nitrosylation and association with nitric oxide synthase. J. Cell Biol. 161, 243–248 (2003).
Bjorkhauk, L., Molnes, J., Sovik, O., Njolstad, P. R. & Flatmark, T. Allosteric activation of human glucokinase by free polyubiquitin chains and its ubiquitin dependent cotranslational proteosomal degradation. J. Biol. Chem. 282, 22757–22764 (2007).
Marshall, S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci. STKE 2006, re7 (2006).
Herman, M. A. & Kahn, B. B. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Invest. 116, 1767–1775 (2006).
Cuesta-Munoz, A. L. et al. The second “de novo” activating mutation (V452L) in a patient with developmental delay. Diabetologia 51 (Suppl. 1), 125 Abstr. 285 (2008).
Christesen, H. B. T. et al. Activating glucokinase GCK mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation Eur. J. Endocrinol. 159, 27–34 (2008).
Wabitsch, M. et al. Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. Diabetic Med. 24, 1393–1399 (2007).
Bertram, L. S. et al. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating
Supported by grants from the National Institutes of Health. Also supported by the Benjamin Rush Endowed Professorship of Biochemistry and Biophysics of the University of Pennsylvania School of Medicine (1984–2004) and financial and material contribution from Hoffman-La Roche (1991 to date). This review benefited immensely from numerous discussion of the topic with Joe Grimsby from Hoffman-La Roche.
The author declares no competing financial interests.
- Hill coefficient
(nH). A measure of the sigmoidal agonist concentration dependency of processes based on cooperative mechanisms.
- Glucose sensing
Signalling events initiated by macromolecules that bind glucose with binding constants in the range of physiologically relevant glucose concentrations of 2–10 mM. The result is usually a positive or negative effect on blood glucose levels.
- Control strength
A concept of control theory that defines the impact of regulatory steps in metabolic pathways measured in terms of a unitless numerical value ranging from 0 to 1, with unity signifying the highest possible impact. This value is the ratio of the fractional change of the rate of the pathway and the fractional change of the rate of activity of an enzyme in the pathway. In β-cell metabolism, glucokinase has a control strength approaching unity.
- Glucose threshold
A well-defined glucose concentration (for example, about 5 mM) at which a cell or a complex tissue (for example, the β-cell or the liver) responds physiologically by generating an effective signal (for example, increased insulin secretion) or changing the direction of glucose flux (for example, from net glucose production to net glucose uptake).
- Relative activity index (AI) of glucokinase
A numerical expression incorporating the major kinetic constants of glucokinase and its mutants relative to the wild-type enzyme constants. AI = (kcat/glucose S0.5nH)×(2.5/(2.5 + ATP Km)) extrapolating to unity for wild-type glucokinase but >1.0 for activating and <1.0 for inactivating mutant enzymes.
About this article
Cite this article
Matschinsky, F. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8, 399–416 (2009). https://doi.org/10.1038/nrd2850
Nature Communications (2022)
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Nature Medicine (2022)
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Nature Medicine (2022)
Nature Reviews Endocrinology (2021)
Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma
Scientific Reports (2021)